Exsight Ventures

http://www.exsightventures.com

Last activity: 07.11.2025

Active

We are a venture capital firm specializing in early-stage impact investments in innovative ophthalmic diagnostic and treatment solutions. The firm consists of 2 accomplished retinal surgeons and a team of investment professionals that have partnered to address the need for funding early stage ophthalmic focused companies. The firm seeks investments in biotechnology, medical devices, pharmaceuticals and software solutions in ophthalmology.

To contact the firm please follow this link: http://www.exsightventures.com/contact.html

News

Mentions

Overview

Location

United States, New York

Employees

1-10

Founded date

2014

Investment Type

Venture Capital

Investment Stage

Pre-Seed; Seed; Series A

News 32

Date	Title	Description
Sign up to see	Sign up to see	Sign up to see
Dec 27, 2021	OIS Year in review	Dr. Rahhal sits down with Craig Simak, OIS co-founder, and fellow OIS podcast hosts, Robert Rothman, MD (InFocus Capital Partners) and Ehsan Sadri, MD, FACS (Visionary Ventures) to discuss the OIS 2021 Year in Review: Shrugging Off the Pand...
Nov 30, 2021	Congratulations to lensgen team on this significant milestone: IDE Approval from the U.S. FDA to Begin Clinical Study	Great news for LensGen, Inc. The approval of their IDE will allow the company to begin their pivotal trial with the ultimate goal of seeking premarket approval. Congratulations to Ram and the team! Their persistence and dedication is inspir...
Jul 7, 2021	ELT Sight: taking "minimally invasive" glaucoma surgery to new heights	ExSight Ventures ("EV") is pleased to announce our investment in ELT Sight, Inc. ("ELT"). ELT is focused on safe and effective microinvasive glaucoma surgery with its next generation ELIOS™ procedure. The funding will en...
Jun 3, 2021	Trefoil Profiled in Ophthalmology Biopharma Dealmakers	An article about Trefoil Therapeutics was included in the May 27 electronic version of a special Innovation in Ophthalmology Biopharma Dealmakers publication. Hard-copies will be published in mid-June. The lead article is titled Partnering ...
Mar 4, 2021	DTx soars to $100 million Series B to advance falcon™Platform	We were first introduced to DTx founder and CEO Artie Suckow in June 2017. DTx formed to unlock RNA therapeutics' promise and overcome challenges inherent in delivering this therapeutic class to an array of different tissues and cell types....
Jan 16, 2021	OUR NEXT GUEST: ON THIS WEEK'S OIS PODCAST DR. RAHHAL HOSTS .... US !	After watching and listening to Dr. Rahhal's many episodes hosting the OIS Retina Podcast we joined him in this week's installment. Firas was having so much fun talking ophthalmic innovation with his other guests we wanted to get in on the ...
Jan 6, 2021	Silver Linings: ExSight's 2020 year in review	The below is taken from an update we shared with our investors, portfolio companies, and friends as 2020 came to a close. We share some of these reflections here as well. We're hopeful and optimistic that 2021 will bring much more positivit...
Dec 22, 2020	Rolling on: ONL Therapeutics closes $46.9 million Series B financing	Beyond retinal detachment, lead candidate ONL1204 will also advance into the chronic conditions of glaucoma and dry age-related macular degeneration ONL Therapeutics, Inc. (“ONL”), a clinical-stage biopharmaceutical company and ExSight Ven...
Dec 22, 2020	Rolling on: ONL Therapeutics closes $46.9 million Series B financing	Beyond retinal detachment, lead candidate ONL1204 will also advance into the chronic conditions of glaucoma and dry age-related macular degeneration ONL Therapeutics, Inc. (“ONL”), a clinical-stage biopharmaceutical company and ExSight Ven...
Oct 6, 2020	Re-vana Therapeutics delivers $3.2 Million oversubscribed round	ExSight Ventures ("ExSight") is pleased to announce our investment Re-Vana Therapeutics, Ltd, ("Re-Vana") to support pre-clinical development of sustained-release biologic and small molecule therapeutics. ExSight is prou...
Aug 28, 2020	LensGen® Closes $10 Million Financing and Welcomes James V. Mazzo to its Board of Directors	LensGen maintains momentum in their work toward an Investigational Device Exemption ("IDE") approval by closing additional financing and adding James (Jim) Mazzo to the board. Jim brings over 40 years of ophthalmic industry experi...
Aug 28, 2020	Podcast potpourri	Dr. Rahhal is quickly becoming a prolific podcaster. In this week's roundup Firas hosts three podcasts with another impressive list of guests offering different perspectives on ophthalmic innovation. In this third OIS Retina Podcast, host ...
Aug 20, 2020	Trefoil Therapeutics Begins First Clinical Trial of Regenerative Treatment for Patients with Corneal Endothelial Dystrophies	One principle guides our investments: invest in companies that will improve patients' lives. We have found that the best founders and executive teams share that belief. From our first meeting to an email this week, the Trefoil Therapeutics ...
Jul 11, 2020	DR. RAHHAL ADDS "HOST" TO HIS MANY TALENTS: INTRODUCING THE OIS RETINA PODCAST	ExSight founding partner, Dr. Firas Rahhal, is no stranger to the OIS stage and has even had a turn as host of OIS TV. Firas discusses this new role below. It has been an honor and a privilege to be invited to host the new OIS-Retina Podca...
Jul 11, 2020	WALL STREET JOURNAL COVERS NEW CROP OF VENTURE FIRMS INCLUDING EXSIGHT	ExSight Ventures was mentioned alongside other specialized venture firms in an article by Brian Gormley in the Wall Street Journal. The article covers the "long-running trend toward specialization in venture capital." Read the art...
Feb 25, 2020	envision diagnostics raises series A Round	ExSight Ventures ("EV") is pleased to announce our continued involvement and additional investment in Envision Diagnostics, Inc. ("Envision"). EV joined existing investors and new investors in Envision’s recent Series A ...
Feb 25, 2020	Exsight announces dtx investment to enable delivery of RNA therapeutics	ExSight Ventures (“EV”) is pleased to announce our investment DTx Pharma, Inc. (“DTx”). DTx is developing technology that will utilize RNA-based therapeutics as the preferred modality for personalized treatment across many therapeutic areas...
Dec 12, 2019	electrifying vision: announcing our investment in 2c tech	ExSight Ventures (“EV”) joined a $10 million Series B financing round in 2C Tech Corporation Inc. (the “Company” or “2C Tech”), an early-stage biotechnology company. 2C Tech is developing nanoparticle technology to treat a number of retinal...
Oct 16, 2019	Introducing The ExSight Ventures Syndicate On AngelList	The ExSight Ventures team is enthusiastically announcing the launch of the ExSight Ventures Syndicate on AngelList! AngelList is a platform site that enables accredited investors to invest in companies and funds. Syndicates “are single-deal...
Aug 16, 2019	HIS KIND OF TOWN: FIRAS HOSTS OIS TV AT OIS@ASRS IN CHICAGO	ExSight Ventures partner, Dr. Firas Rahhal is not a stranger to the stage at the various Ophthalmology Innovation Summit meetings (AAO, ASCRS) and has even appeared on OIS TV as an interviewee (here). Though based in Los Angeles Firas made ...
Aug 16, 2019	dr. rahhal discusses funding opthalmic innovation at ois@ascrs 2019 in san diego	The OIS meetings always keep us busy with a full slate of meetings. These one-day conferences occur around various ophthalmology academy and society meetings throughout the year. OIS unites key constituents in ophthalmic innovation, includi...
Aug 16, 2019	Announcing our next fund: proof of concept	ExSight’s second fund, 8th Line II held a first close May 27 with participation from many of our existing investors. We also welcomed several new investors. The focus remains the same: to invest in the most innovative companies working to p...
Aug 16, 2019	LEnsgen is the talk of the town @ Ascrs 2019	LensGen, an ExSight Ventures portfolio company, was the buzz of this year's American Society of Cataract and Refractive Surgery meeting (“ASCRS”) in San Diego. Members of the ExSight team were in the audience to hear Drs. Eric Donnenfeld, U...
Jul 23, 2019	Trefoil moves closer to a clinical trial: Announcing our follow on investment	Trefoil Therapeutics, Inc., an early-stage biopharmaceutical company and ExSight Ventures portfolio company, announced their $28 million Series A financing. Trefoil is developing a regenerative approach to treating corneal dystrophies and o...
Feb 27, 2019	Qura's promise: enable smarter treatment decisions based on better information	ExSight is pleased to announce Qura, Inc. (“Qura”) as the fifth and final portfolio company for 8th Line Investments, LLC. Qura is developing a miniaturized pressure sensor for the measurement of intraocular pressure (“IOP”) in patients wit...
Sep 27, 2018	ONL Therapeutics is pioneering an entirely new approach to preserving sight and halting vision loss	ExSight is happy to announce an investment in ONL Therapeutics, Inc., an early stage biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases. ExSight participated in a convertible note financ...
Sep 17, 2018	Exsight partner alan spiro joins innovative odylia therapeutics	Alan is on the Board of Advisors of Odylia Therapeutics. Odylia has created a novel paradigm to catalyze the development of gene therapies for rare blinding inherited retinal diseases (IRDs). Its strategy is to provide a non-profit platform...
Aug 7, 2018	ExSight partner dr. rahhal at OIS@ASRS	This summer Dr. Rahhal participated in a panel discussion at the Ophthalmology Innovation Summit at the Americas Society for Retina Specialists meeting in Vancouver. The Ophthalmology Innovation Summits unite industry, entrepreneurial and c...
Aug 2, 2018	Lensgen hitting milestones and broadening patent protection	ExSight portfolio company LensGen announced additional financing and patent grants. LensGen is developing the world's first modular, fluid-optic, curvature changing intraocular lens ("IOL"). LensGen “achieved a key clinical perfor...
Jul 20, 2018	the exsight ventures thesis	We’re often asked, “why ophthalmology”? We enthusiastically respond with some variation of an answer that includes a combination of our deep domain expertise, market insights, technological breakthroughs and attractive investment returns. T...
Jul 20, 2018	Dr. rahhal co-authors breakthrough stem cell Transplant trial targeting vision loss	Over the last several months the press has been abuzz with the promising results of two recent, unrelated clinical studies. Each was the study of stem cell transplantation in patients with age-related macular degeneration (“AMD”). The first...

Mentions in press and media 2

Date	Title	Description
Sign up to see	Sign up to see	Sign up to see
Nov 6, 2025	ExSight Ventures Invests In DefEYE To Advance Decellularized Placental-Based Ocular Biologics	ExSight Ventures has invested in DefEYE, a company specializing in the development of decellularized placental-based biologic solutions for ocular care. The funding supports DefEYE’s efforts to commercialize its technology and expand its po...

Reviews 0

FAQ about Exsight Ventures

When was Exsight Ventures founded?

Exsight Ventures was founded in 2014.

What is the latest news about Exsight Ventures?

Parsers VC has 32 news items about Exsight Ventures, among them “OIS Year in review” (Dec 27, 2021) and “Congratulations to lensgen team on this significant milestone: IDE Approval from the U.S. FDA to Begin Clinical Study” (Nov 30, 2021).

What has the press written about Exsight Ventures?

Parsers VC has collected 2 articles mentioning Exsight Ventures, among them “ExSight Ventures Invests In DefEYE To Advance Decellularized Placental-Based Ocular Biologics” (Nov 6, 2025).

Is Exsight Ventures still active?

Yes, Exsight Ventures is active; its latest activity on Parsers VC dates from Nov 7, 2025.